Literature DB >> 19890216

Short-term bone loss in HIV-infected premenopausal women.

Michael T Yin1, Dalian Lu, Serge Cremers, Phyllis C Tien, Mardge H Cohen, Qiuhu Shi, Elizabeth Shane, Elizabeth T Golub, Kathryn Anastos.   

Abstract

BACKGROUND: Low bone mineral density (BMD) has been reported in HIV+ women, but less is known about the longitudinal evolution of BMD and fracture incidence.
METHODS: In 100 HIV+ and 68 HIV- premenopausal women in the Women's Interagency HIV Study, BMD was measured by dual energy x-ray absorptiometry at the femoral neck (FN) and lumbar spine (LS) at index visit and after a median of 2.5 years.
RESULTS: In HIV+ women, BMD at index visit was normal but 5% lower at the LS and FN than in HIV- women. Annual percent decrease in BMD did not differ between HIV+ and HIV- women at the LS (-0.8% +/- 0.2% vs -0.4% +/- 0.2%, P = 0.20) or FN (-0.8% +/- 0.3% vs -0.6% +/- 0.3%, P = 0.56) and remained similar after adjustment for age, weight, and BMD at index visit. Among HIV+ women, bone loss was associated with vitamin D deficiency and opiate use but not with use or class of antiretrovirals. Incidence of self-reported fracture was 0.74 per 100 person-years in HIV+ women and similar in HIV- women.
CONCLUSIONS: In premenopausal HIV+ women, index BMD was lower than comparable HIV- women; however, rates of bone loss at the LS and FN were similar over 2.5 years of observation, irrespective of antiretroviral therapy.

Entities:  

Mesh:

Year:  2010        PMID: 19890216      PMCID: PMC2813405          DOI: 10.1097/QAI.0b013e3181bf6471

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  35 in total

1.  Intracellular cytokines in the acute response to highly active antiretroviral therapy.

Authors:  E Lew; L Gallagher; M Kuehnert; D Rimland; M Hubbard; B Parekh; E Zell; W Jarvis; J Jason
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

2.  Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy.

Authors:  N A Hessol; M Schneider; R M Greenblatt; M Bacon; Y Barranday; S Holman; E Robison; C Williams; M Cohen; K Weber
Journal:  Am J Epidemiol       Date:  2001-09-15       Impact factor: 4.897

3.  Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir.

Authors:  D Nolan; R Upton; E McKinnon; M John; I James; B Adler; G Roff; S Vasikaran; S Mallal
Journal:  AIDS       Date:  2001-07-06       Impact factor: 4.177

4.  Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy.

Authors:  Dario Bruera; Norma Luna; Daniel O David; Liliana M Bergoglio; Javier Zamudio
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

Review 5.  Diagnosis of osteoporosis and assessment of fracture risk.

Authors:  John A Kanis
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

6.  Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals.

Authors:  Kristin Mondy; Kevin Yarasheski; William G Powderly; Michael Whyte; Sherry Claxton; Debra DeMarco; Mary Hoffmann; Pablo Tebas
Journal:  Clin Infect Dis       Date:  2003-01-29       Impact factor: 9.079

7.  Reduced testosterone levels in human immunodeficiency virus-infected women with weight loss and low weight.

Authors:  Jeannie S Huang; Stephanie J Wilkie; Sara Dolan; James H Gallafent; Negar Aliabadi; Meghan P Sullivan; Steven Grinspoon
Journal:  Clin Infect Dis       Date:  2003-01-28       Impact factor: 9.079

8.  Osteopenia in HIV-infected women prior to highly active antiretroviral therapy.

Authors:  J Teichmann; E Stephan; U Lange; T Discher; G Friese; J Lohmeyer; H Stracke; R G Bretzel
Journal:  J Infect       Date:  2003-05       Impact factor: 6.072

9.  Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.

Authors:  J Fernández-Rivera; R García; F Lozano; J Macías; J A García-García; J A Mira; J E Corzo; J Gómez-Mateos; A Rueda; J Sánchez-Burson; J A Pineda
Journal:  HIV Clin Trials       Date:  2003 Sep-Oct

10.  Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.

Authors:  Todd T Brown; Grace A McComsey; Martin S King; Roula B Qaqish; Barry M Bernstein; Barbara A da Silva
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.771

View more
  31 in total

1.  Bone disease in HIV infection.

Authors:  Maristella Francesca Saccomanno; Adriana Ammassari
Journal:  Clin Cases Miner Bone Metab       Date:  2011-01

2.  HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study.

Authors:  Phyllis C Tien; Michael F Schneider; Christopher Cox; Mardge Cohen; Roksana Karim; Jason Lazar; Mary Young; Marshall J Glesby
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

3.  Prospective evaluation of bone mineral density among middle-aged HIV-infected and uninfected women: Association between methadone use and bone loss.

Authors:  Anjali Sharma; Hillel W Cohen; Ruth Freeman; Nanette Santoro; Ellie E Schoenbaum
Journal:  Maturitas       Date:  2011-09-25       Impact factor: 4.342

4.  Prospective study of bone mineral density changes in aging men with or at risk for HIV infection.

Authors:  Anjali Sharma; Peter L Flom; Jeremy Weedon; Robert S Klein
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

5.  Racial differences in bone loss and relation to menopause among HIV-infected and uninfected women.

Authors:  Anjali Sharma; Peter L Flom; Clifford J Rosen; Ellie E Schoenbaum
Journal:  Bone       Date:  2015-04-18       Impact factor: 4.398

Review 6.  Vitamin D in HIV-Infected Patients.

Authors:  Jordan E Lake; John S Adams
Journal:  Curr HIV/AIDS Rep       Date:  2011-09       Impact factor: 5.071

7.  Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.

Authors:  K M Klassen; M G Kimlin; C K Fairley; S Emery; P H Anderson; P R Ebeling
Journal:  Osteoporos Int       Date:  2015-12-11       Impact factor: 4.507

8.  Increased Fracture Incidence in Middle-Aged HIV-Infected and HIV-Uninfected Women: Updated Results From the Women's Interagency HIV Study.

Authors:  Anjali Sharma; Qiuhu Shi; Donald R Hoover; Kathryn Anastos; Phyllis C Tien; Mary A Young; Mardge H Cohen; Elizabeth T Golub; Deborah Gustafson; Michael T Yin
Journal:  J Acquir Immune Defic Syndr       Date:  2015-09-01       Impact factor: 3.731

Review 9.  Bone Loss Among Women Living With HIV.

Authors:  M Neale Weitzmann; Ighovwerha Ofotokun; Kehmia Titanji; Anjali Sharma; Michael T Yin
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

10.  Improved fracture prediction using different fracture risk assessment tool adjustments in HIV-infected women.

Authors:  Jingyan Yang; Anjali Sharma; Qiuhu Shi; Kathryn Anastos; Mardge H Cohen; Elizabeth T Golub; Deborah Gustafson; Daniel Merenstein; Wendy J Mack; Phyllis C Tien; Jeri W Nieves; Michael T Yin
Journal:  AIDS       Date:  2018-07-31       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.